This page contains regularly updated information on Realm Therapeutics AIM securities and the Company's most significant shareholders. Realm Therapeutics is traded on AIM and no other Exchanges. There are no restrictions on the trading of Realm Therapeutics' shares
As of 30 November 2018
Number of AIM securities in issue: 116,561,917 10p Ords
There are no shares held in treasury.
Percentage of AIM Securities not in public hands: 35.62%
As of 30 November 2018, the following shareholders held interests in excess of 3% of ordinary share capital.
|BVF Partners LP||15,322,266||13.15%|
|Invesco Asset Management, as agent for and on behalf of its discretionary managed clients||9,596,965||8.23%|
|Abingworth BioEquities Master Fund Ltd.||6,384,277||5.48%|
|Sussex Trading Company Limited||6,148,880||5.28%|
|Oracle Management Limited||5,410,196||4.64%|
|Sphera Master Funds||4,900,000||4.20%|
|Kanton Services Limited||4,629,196||3.97%|
|Polar Capital Funds Plc||3,500,000||3.00%|
* Executive Director